K
Kamada Ltd. (KMDA)
NMS – Real Time Price. Currency in USD
8.43
-0.02 (-0.24%)
At close: May 12, 2026, 4:00 PM EDT
8.99
+0.56 (6.64%)
After-hours: May 12, 2026, 7:49 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
8.43
-0.02 (-0.24%)
At close: May 12, 2026, 4:00 PM EDT
8.99
+0.56 (6.64%)
After-hours: May 12, 2026, 7:49 PM EDT
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
| Name | Position |
|---|---|
| Mr. Amir London | Chief Executive Officer |
| Mr. Boris Gorelik | Vice President of Business Development & Strategic Programs |
| Mr. Chaime Orlev | Chief Financial Officer |
| Mr. David Tsur | Co-Founder & Independent Deputy Chairman of the Board |
| Mr. Eran Nir | Chief Operating Officer |
| Mr. Jon R. Knight | Vice President of US Commercial Operations |
| Mr. Nir Livneh B.A., L.L.B. | VP, General Counsel & Corporate Secretary |
| Ms. Hanni Neheman | Vice President of Marketing & Sales |
| Ms. Liron Reshef | Vice President of Human Resources |
| Ms. Shavit Beladev | Vice President of Kamada Plasma |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 6-K | ea0289381-6k_kamada.htm |
| 2026-03-31 | 6-K | ea0283955-6k_kamada.htm |
| 2026-03-26 | 6-K | ea0283431-6k_kamada.htm |
| 2026-03-17 | 6-K | ea0281980-6k_kamada.htm |
| 2026-03-11 | 6-K | ea0280560-6k_kamada.htm |
| 2026-03-04 | 6-K | ea0279964-6k_kamada.htm |
| 2026-01-07 | 6-K | ea0272041-6k_kamada.htm |
| 2025-12-18 | 6-K | ea0270198-6k_kamada.htm |
| 2025-12-10 | 6-K | ea0269087-6k_kamada.htm |
| 2025-12-08 | 6-K | ea0268786-6k_kamada.htm |